Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire•04/11/2026•17:00 ET
0
Key Highlights
- ➤Puma granted inducement RSUs covering 18,500 shares to three new employees
- ➤Awards vest over three years, subject to continued service
- ➤Puma initiated ALISCA-Lung2 Phase II trial in September 2026
- ➤Puma’s NERLYNX is FDA-approved for multiple HER2-positive breast cancer indications
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 2, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 18,500 shares of Puma common stock to three new non-executive employees.
Get started
Create a free account to read the full story.